ELOX (Eloxx Pharmaceuticals) Enterprise Value: $37.61 Mil (As of Jun. 27, 2026) ***


ELOX Eloxx Pharmaceuticals Inc ELOX
17 GF Score
Price $12.05
! 1 Warning Sign
View Full Analysis

What is Eloxx Pharmaceuticals Enterprise Value?

Eloxx Pharmaceuticals ELOX +5.57% 17 Enterprise Value is $37.61 Mil as of Jun. 27, 2026. GuruFocus rates ELOX with a GF Score™ of 17/100. The stock has 1 warning sign investors should review.

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Eloxx Pharmaceuticals's Enterprise Value is $37.61 Mil. Eloxx Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.95 Mil. Therefore, Eloxx Pharmaceuticals's EV-to-EBIT ratio for today is -7.60.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Eloxx Pharmaceuticals's Enterprise Value is $37.61 Mil. Eloxx Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.95 Mil. Therefore, Eloxx Pharmaceuticals's EV-to-EBITDA ratio for today is -7.60.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Eloxx Pharmaceuticals's Enterprise Value is $37.61 Mil. Eloxx Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil. Therefore, Eloxx Pharmaceuticals's EV-to-Revenue ratio for today is .

EV-to-OCF is calculated as Enterprise Value divided by its Cash Flow from Operations. As of today, Eloxx Pharmaceuticals's Enterprise Value is $37.61 Mil. Eloxx Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-6.33 Mil. Therefore, Eloxx Pharmaceuticals's EV-to-OCF ratio for today is -5.94.

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Eloxx Pharmaceuticals's Enterprise Value is $37.61 Mil. Eloxx Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-6.33 Mil. Therefore, Eloxx Pharmaceuticals's EV-to-FCF ratio for today is -5.94.

*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.


Eloxx Pharmaceuticals  (NAS:ELOX) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Eloxx Pharmaceuticals's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=37.605/-4.946
=-7.60

Eloxx Pharmaceuticals's current Enterprise Value is $37.61 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Eloxx Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.95 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Eloxx Pharmaceuticals's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=37.605/-4.946
=-7.60

Eloxx Pharmaceuticals's current Enterprise Value is $37.61 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Eloxx Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.95 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Eloxx Pharmaceuticals's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=37.605/0
=

Eloxx Pharmaceuticals's current Enterprise Value is $37.61 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Eloxx Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.

4. EV-to-OCF is calculated as Enterprise Value divided by its Cash Flow from Operations.

Eloxx Pharmaceuticals's EV-to-OCF for today is:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=37.605/-6.327
=-5.94

Eloxx Pharmaceuticals's current Enterprise Value is $37.61 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Eloxx Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-6.33 Mil.

5. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Eloxx Pharmaceuticals's EV-to-FCF for today is:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=37.605/-6.327
=-5.94

Eloxx Pharmaceuticals's current Enterprise Value is $37.61 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Eloxx Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-6.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eloxx Pharmaceuticals Enterprise Value Related Terms


Eloxx Pharmaceuticals Enterprise Value Historical Data

* Premium members only.

The historical data trend for Eloxx Pharmaceuticals's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eloxx Pharmaceuticals Enterprise Value Chart

Eloxx Pharmaceuticals Annual Data
Trend Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.40 -1.88 6.61 6.41 -3.78

Eloxx Pharmaceuticals Semi-Annual Data
Jun06 Jun07 Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.40 -1.88 6.61 6.41 -3.78

ELOX vs CPMV, OGEN, CASIF: Enterprise Value Comparison

For the Biotechnology subindustry, Eloxx Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eloxx Pharmaceuticals Enterprise Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eloxx Pharmaceuticals's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Eloxx Pharmaceuticals's Enterprise Value falls into.


ELOX
17GF Score
Eloxx Pharmaceuticals Inc ELOX
Enterprise Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eloxx Pharmaceuticals Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Eloxx Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as

Eloxx Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Enterprise Value →
What does a Enterprise Value of $37.61 Mil mean?
Eloxx Pharmaceuticals (ELOX) has a Enterprise Value of $37.61 Mil as of Jun. 27, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Eloxx Pharmaceuticals and its competitors.
Is Eloxx Pharmaceuticals' Enterprise Value too high?
Eloxx Pharmaceuticals' current Enterprise Value is $37.61 Mil. Overall, Eloxx Pharmaceuticals has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Eloxx Pharmaceuticals' Enterprise Value compare to CPMV and OGEN?
Eloxx Pharmaceuticals' Enterprise Value of $37.61 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Eloxx Pharmaceuticals and its competitors. Eloxx Pharmaceuticals's current Enterprise Value is $37.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eloxx Pharmaceuticals stock overvalued right now?
Eloxx Pharmaceuticals (ELOX) has a current Enterprise Value of $37.61 Mil. The current Enterprise Value is $37.61 Mil. Eloxx Pharmaceuticals' overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Eloxx Pharmaceuticals (ELOX), the current Enterprise Value is $37.61 Mil as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eloxx Pharmaceuticals Business Description

Address 10 Court Street, P.O. Box 274, Arlington, MA, USA, 02476
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
17GF Score

Get the complete analysis for ELOX

Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.05
Price